{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:44:05Z","timestamp":1792701845072,"version":"4.5.0"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Olanzapine is an atypical antipsychotic used to treat schizophrenia and manic episodes. Its potential thromboembolic risk has been reported, but the evidence remains controversial. This study aimed to comprehensively evaluate the association between olanzapine and pulmonary embolism (PE) and venous thromboembolism (VTE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study combined meta-analysis and signal mining from the FDA Adverse Event Reporting System (FAERS) database to assess the association between olanzapine and pulmonary embolism (PE) and venous thromboembolism (VTE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      From 55,905 olanzapine-related adverse event reports in the Faers database, 1,233 significant signals were identified, including serious adverse events not fully documented on the drug label, such as pulmonary embolism and venous embolism. A meta-analysis of eight studies showed that olanzapine use significantly increased the risk of VTE and pulmonary embolism (OR = 2.07, 95% CI: 1.37\u20133.14,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.0006).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings suggest that olanzapine is associated with an increased risk of thromboembolic events; therefore, enhanced clinical surveillance and further investigation into its safety are necessary.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420251003254.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1710507","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T07:03:22Z","timestamp":1770793402000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Thromboembolic events with olanzapine: a systematic review integrating meta-analysis and FAERS database"],"prefix":"10.3389","volume":"13","author":[{"given":"XueSong","family":"Zhang","sequence":"first","affiliation":[{"name":"School of Pharmacy, Shaanxi University of Chinese Medicine","place":["Xianyang, China"]},{"name":"New Drug Safety Evaluation Center, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SiMan","family":"Sun","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Shaanxi University of Chinese Medicine","place":["Xianyang, China"]},{"name":"New Drug Safety Evaluation Center, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiaoYu","family":"Fan","sequence":"additional","affiliation":[{"name":"New Drug Safety Evaluation Center, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShuShu","family":"Guo","sequence":"additional","affiliation":[{"name":"College of Life Sciences and Biopharmaceuticals, Shenyang Pharmaceutical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WanFang","family":"Li","sequence":"additional","affiliation":[{"name":"New Drug Safety Evaluation Center, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Beijing, China"]},{"name":"Beijing Union-Genius Pharmaceutical Technology Development Co., Ltd.","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Shaanxi University of Chinese Medicine","place":["Xianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ChongZe","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fuzhou Changle People\u2019s District Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HongTao","family":"Jin","sequence":"additional","affiliation":[{"name":"New Drug Safety Evaluation Center, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Beijing, China"]},{"name":"Beijing Union-Genius Pharmaceutical Technology Development Co., Ltd.","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Key Technologies for Preclinical Research and Development of Innovative Drugs in Pharmacokinetics and Pharmacodynamics","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.3390\/biomedicines11071917","article-title":"The role of dopamine in repurposing drugs for oncology","volume":"11","author":"Moura","year":"2023","journal-title":"Biomedicines"},{"key":"B2","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/YIC.0000000000000038","article-title":"Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study","volume":"29","author":"McDonnell","year":"2014","journal-title":"Int Clin Psychopharmacol"},{"key":"B3","article-title":"Olanzapine","volume-title":"StatPearls","author":"Thomas","year":"2025"},{"key":"B4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1055\/s-0038-1642036","article-title":"Epidemiology, pathophysiology, and natural history of pulmonary embolism","volume":"35","author":"Turetz","year":"2018","journal-title":"Semin Intervent Radiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1056\/NEJMra0907731","article-title":"Acute pulmonary embolism","volume":"363","author":"Agnelli","year":"2010","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.21037\/cdt.2018.01.09","article-title":"Chronic pulmonary embolism: diagnosis","volume":"8","author":"Nishiyama","year":"2018","journal-title":"Cardiovasc Diagn Ther"},{"key":"B7","article-title":"Acute pulmonary embolism","volume-title":"StatPearls","author":"Vyas","year":"2025"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11239-015-1311-6","article-title":"The epidemiology of venous thromboembolism","volume":"41","author":"Heit","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3389\/fpsyt.2019.00330","article-title":"Venous thromboembolism as an adverse effect during treatment with olanzapine: a case series","volume":"10","author":"Masopust","year":"2019","journal-title":"Front Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1757-1626-3-36","article-title":"Olanzapine and pulmonary embolism, a rare association: a case report","volume":"3","author":"Maempel","year":"2010","journal-title":"Cases J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1097\/00001648-199710000-00010","article-title":"Mortality in current and former users of clozapine","volume":"8","author":"Walker","year":"1997","journal-title":"Epidemiology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"5138509","DOI":"10.1155\/2021\/5138509","article-title":"Acute pulmonary embolism associated with low-dose olanzapine in a patient without risk factors for venous thromboembolism","volume":"2021","author":"Vu","year":"2021","journal-title":"Case Rep Vasc Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1136\/bmj.327.7428.1384","article-title":"Pulmonary embolism possibly associated with olanzapine treatment","volume":"327","author":"Waage","year":"2003","journal-title":"Br Med J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/PAF.0b013e31818736e0","article-title":"Olanzapine: a new risk factor for pulmonary embolus?","volume":"29","author":"Kannan","year":"2008","journal-title":"Am J Forensic Med Pathol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1001\/archinte.165.22.2677","article-title":"Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents","volume":"165","author":"Liperoti","year":"2005","journal-title":"Arch Intern Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e05805","DOI":"10.1002\/ccr3.5805","article-title":"Is there association of olanzapine and pulmonary embolism: a case report","volume":"10","author":"Wang","year":"2022","journal-title":"Clin Case Rep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1582.e5","DOI":"10.1016\/j.ajem.2017.07.026","article-title":"Acute massive pulmonary embolism assoc\u0131ated w\u0131th olanzap\u0131ne","volume":"35","author":"Keles","year":"2017","journal-title":"Am J Emerg Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.pharep.2017.12.003","article-title":"The impact of antipsychotics as a risk factor for thromboembolism","volume":"70","author":"Og\u0142odek","year":"2018","journal-title":"Pharmacol Rep"},{"key":"B19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/B978-0-12-803376-0.00003-4","article-title":"Chapter 3\u2014pulmonary embolism","volume-title":"Life-Threatening Effects of Antipsychotic Drugs","author":"Manu","year":"2016"},{"key":"B20","doi-asserted-by":"publisher","first-page":"736","DOI":"10.5498\/wjp.v11.i10.736","article-title":"Antipsychotics cardiotoxicity: what\u2019s known and what\u2019s next","volume":"11","author":"Li","year":"2021","journal-title":"World J Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejim.2018.02.030","article-title":"Antipsychotic drugs and the risk of recurrent venous thromboembolism: a prospective cohort study","volume":"52","author":"Mollard","year":"2018","journal-title":"Eur J Intern Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2045125320982720","DOI":"10.1177\/2045125320982720","article-title":"Current antipsychotic agent use and risk of venous thromboembolism and pulmonary embolism: a systematic review and meta-analysis of observational studies","volume":"11","author":"Liu","year":"2021","journal-title":"Ther Adv Psychopharmacol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"101967","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database","volume":"59","author":"Zhou","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e15734056306358","DOI":"10.2174\/0115734056306358240607115422","article-title":"Hypersensitivity reactions induced by iodinated contrast Media in radiological diagnosis: a disproportionality analysis based on the FAERS database","volume":"20","author":"Long","year":"2024","journal-title":"Curr Med Imaging"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1339721","DOI":"10.3389\/fphar.2024.1339721","article-title":"A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for denosumab","volume":"15","author":"He","year":"2024","journal-title":"Front Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1226086","DOI":"10.3389\/fphar.2023.1226086","article-title":"Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system","volume":"14","author":"Xiong","year":"2023","journal-title":"Front Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B29","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/cam4.485","article-title":"Optimal management of cervical cancer in HIV-positive patients: a systematic review","volume":"4","author":"Ntekim","year":"2015","journal-title":"Cancer Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"B32","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Br Med J"},{"key":"B33","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3389\/fphar.2019.00846","article-title":"Olanzapine-induced hyperprolactinemia: two case reports","volume":"10","author":"Barata","year":"2019","journal-title":"Front Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s40264-025-01520-1","article-title":"Leveraging FDA labeling documents and large language model to enhance annotation, profiling, and classification of drug adverse events with AskFDALabel","volume":"48","author":"Wu","year":"2025","journal-title":"Drug Saf"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/pds.3699","article-title":"Antipsychotic drugs and risk of idiopathic venous thromboembolism: a nested case-control study using the CPRD","volume":"23","author":"Ishiguro","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/pds.2210","article-title":"Antipsychotic drugs and risk of pulmonary embolism","volume":"21","author":"Allenet","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B37","doi-asserted-by":"publisher","first-page":"c4245","DOI":"10.1136\/bmj.c4245","article-title":"Antipsychotic drugs and risk of venous thromboembolism: nested case-control study","volume":"341","author":"Parker","year":"2010","journal-title":"Br Med J"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1080\/14740338.2024.2396390","article-title":"Association between antipsychotics and pulmonary embolism: a pharmacovigilance analysis","volume":"24","author":"Huang","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"B39","doi-asserted-by":"publisher","first-page":"14791641241236894","DOI":"10.1177\/14791641241236894","article-title":"A pharmacoepidemiological nested case-control study of risk factors for venous thromboembolism with the focus on diabetes, cancer, socioeconomic group, medications, and comorbidities","volume":"21","author":"Myllylahti","year":"2024","journal-title":"Diab Vasc Dis Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1080\/14740338.2023.2251881","article-title":"A pharmacovigilance study of the association between antipsychotic drugs and venous thromboembolism based on food and drug administration adverse event reporting system data","volume":"23","author":"Yan","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1160\/TH15-11-0895","article-title":"Use of antipsychotics and risk of venous thromboembolism in postmenopausal women. A population-based nested case-control study","volume":"115","author":"Wang","year":"2016","journal-title":"Thromb Haemost"},{"key":"B42","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.schres.2015.01.012","article-title":"A population-based cohort study on deep vein thrombosis and pulmonary embolism among schizophrenia patients","volume":"162","author":"Hsu","year":"2015","journal-title":"Schizophr Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40263-018-0495-7","article-title":"Venous thromboembolism during treatment with antipsychotics: a review of current evidence","volume":"32","author":"J\u00f6nsson","year":"2018","journal-title":"CNS Drugs"},{"key":"B44","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e68626","DOI":"10.7759\/cureus.68626","article-title":"Olanzapine-induced acute pulmonary embolism","volume":"16","author":"Moussaoui","year":"2024","journal-title":"Cureus"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1038\/s41598-018-36930-y","article-title":"Chronic olanzapine administration causes metabolic syndrome through inflammatory cytokines in rodent models of insulin resistance","volume":"9","author":"Li","year":"2019","journal-title":"Sci Rep"},{"key":"B47","doi-asserted-by":"publisher","first-page":"5320","DOI":"10.1038\/s41598-021-84586-y","article-title":"Metabolic consequences of obesity on the hypercoagulable state of polycystic ovary syndrome","volume":"11","author":"Moin","year":"2021","journal-title":"Sci Rep"},{"key":"B48","doi-asserted-by":"publisher","first-page":"935362","DOI":"10.3389\/fphar.2022.935362","article-title":"Alterations in sorting and secretion of hepatic apoA5 induce hypertriglyceridemia due to short-term use of olanzapine","volume":"13","author":"Huang","year":"2022","journal-title":"Front Pharmacol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"20451253231200257","DOI":"10.1177\/20451253231200257","article-title":"Hypercoagulable state in patients with schizophrenia: different effects of acute and chronic antipsychotic medications","volume":"13","author":"Zheng","year":"2023","journal-title":"Ther Adv Psychopharmacol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.3390\/biomedicines12071403","article-title":"Olanzapine modulate lipid metabolism and adipose tissue accumulation via hepatic muscarinic M3 receptor-mediated Alk-related signaling","volume":"12","author":"Su","year":"2024","journal-title":"Biomedicines"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2457687","DOI":"10.1155\/2022\/2457687","article-title":"T lymphocyte-derived exosomes transport MEK1\/2 and ERK1\/2 and induce NOX4-dependent oxidative stress in cardiac microvascular endothelial cells","volume":"2022","author":"Rolski","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"B52","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3390\/biom11020253","article-title":"Role of vascular endothelial growth factor (VEGF) in human embryo implantation: clinical implications","volume":"11","author":"Guo","year":"2021","journal-title":"Biomolecules"},{"key":"B53","doi-asserted-by":"publisher","first-page":"16438","DOI":"10.1038\/s41598-019-52590-y","article-title":"Blockade of multiple monoamines receptors reduce insulin secretion from pancreatic \u03b2-cells","volume":"9","author":"Nagata","year":"2019","journal-title":"Sci Rep"},{"key":"B54","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.1176\/appi.neuropsych.12080201","article-title":"Pulmonary thromboembolism associated with clozapine","volume":"25","author":"Chate","year":"2013","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"B55","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.psyneuen.2017.12.004","article-title":"Obesity exacerbates the acute metabolic side effects of olanzapine","volume":"88","author":"Townsend","year":"2018","journal-title":"Psychoneuroendocrinology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jemermed.2007.07.074","article-title":"Pulmonary thromboembolism associated with olanzapine and risperidone","volume":"35","author":"Borras","year":"2008","journal-title":"J Emerg Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"718950","DOI":"10.1155\/2013\/718950","article-title":"Pulmonary embolism related to amisulpride treatment: a case report","volume":"2013","author":"Skokou","year":"2013","journal-title":"Case Rep Psychiatry"},{"key":"B58","doi-asserted-by":"publisher","first-page":"930","DOI":"10.2174\/1389450121666200422084414","article-title":"The association and influencing factors between antipsychotics exposure and the risk of VTE and PE: a systematic review and meta-analysis","volume":"21","author":"Dai","year":"2020","journal-title":"Curr Drug Targets"},{"key":"B59","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3390\/ijms25020818","article-title":"COVID-19 and antipsychotic therapy: unraveling the thrombosis risk","volume":"25","author":"Dho-Nagy","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B60","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2165\/00023210-200216110-00005","article-title":"Antipsychotic-induced venous thromboembolism\u2014a review of the evidence","volume":"16","author":"Haegg","year":"2002","journal-title":"CNS Drugs"},{"key":"B61","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11239-020-02331-0","article-title":"Serotonin: a platelet hormone modulating cardiovascular disease","volume":"52","author":"Rieder","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e101347","DOI":"10.1136\/gpsych-2023-101347","article-title":"New role of platelets in schizophrenia: predicting drug response","volume":"37","author":"Zhang","year":"2024","journal-title":"Gen Psychiatr"},{"key":"B63","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S0278-5846(01)00258-5","article-title":"Olanzapine-induced agranulocytosis: a case report and review of the literature","volume":"26","author":"Tolosa-Vilella","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B64","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.psyneuen.2008.08.016","article-title":"Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever","volume":"34","author":"Kluge","year":"2009","journal-title":"Psychoneuroendocrinology"},{"key":"B65","doi-asserted-by":"publisher","first-page":"172826","DOI":"10.1016\/j.ejphar.2019.172826","article-title":"Dopamine attenuates lipopolysaccharide-induced expression of proinflammatory cytokines by inhibiting the nuclear translocation of NF-\u03baB p65 through the formation of dopamine quinone in microglia","volume":"866","author":"Yoshioka","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e58493","DOI":"10.7759\/cureus.58493","article-title":"Severe syndrome of inappropriate antidiuretic hormone secretion (SIADH) following the initiation of valbenazine for tardive dyskinesia: a case report","volume":"16","author":"Adelakun","year":"2024","journal-title":"Cureus"},{"key":"B67","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/pcn.12435","article-title":"Clozapine improved the syndrome of inappropriate antidiuretic hormone secretion in a patient with treatment-resistant schizophrenia","volume":"70","author":"Fujimoto","year":"2016","journal-title":"Psychiatry Clin Neurosci"},{"key":"B68","doi-asserted-by":"publisher","first-page":"878","DOI":"10.4103\/jfmpc.jfmpc_205_17","article-title":"A case report of rapid-onset hyponatremia induced by low-dose olanzapine","volume":"6","author":"Anil","year":"2017","journal-title":"J Fam Med Prim Care"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e47719","DOI":"10.7759\/cureus.47719","article-title":"Treatment of psychogenic polydipsia and hyponatremia: a case report","volume":"15","author":"Hurwit","year":"2023","journal-title":"Cureus"},{"key":"B70","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12888-016-0776-y","article-title":"Eosinophilic myocarditis during treatment with olanzapine\u2014report of two possible cases","volume":"16","author":"Vang","year":"2016","journal-title":"BMC Psychiatry"},{"key":"B71","doi-asserted-by":"publisher","first-page":"105714","DOI":"10.1016\/j.phrs.2021.105714","article-title":"Second-generation antipsychotics induce cardiotoxicity by disrupting spliceosome signaling: implications from proteomic and transcriptomic analyses","volume":"170","author":"Wang","year":"2021","journal-title":"Pharmacol Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3390\/ph16040603","article-title":"Receptors involved in mental disorders and the use of clozapine, chlorpromazine, olanzapine, and aripiprazole to treat mental disorders","volume":"16","author":"Mlambo","year":"2023","journal-title":"Pharmaceuticals"},{"key":"B73","doi-asserted-by":"publisher","first-page":"15","DOI":"10.18388\/abp.2020_2871","article-title":"Olanzapine-mediated cardiotoxicity is associated with altered energy metabolism in isolated rat hearts","volume":"67","author":"Gulac","year":"2020","journal-title":"Acta Biochim Pol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"663","DOI":"10.11909\/j.issn.1671-5411.2021.08.002","article-title":"Atypical antipsychotics and oxidative cardiotoxicity: review of literature and future perspectives to prevent sudden cardiac death","volume":"18","author":"D'Errico","year":"2021","journal-title":"J Geriatr Cardiol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/jamapsychiatry.2024.1441","article-title":"Pneumonia risk, antipsychotic dosing, and anticholinergic burden in schizophrenia","volume":"81","author":"Luykx","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"B76","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S2215-0366(24)00223-2","article-title":"Antipsychotic exposure and infection risk in people with schizophrenia spectrum disorders during the COVID-19 pandemic: a Danish nationwide registry study","volume":"11","author":"Nersesjan","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1448623","DOI":"10.3389\/fpsyt.2024.1448623","article-title":"Dysphagia in schizophrenia: pathological mechanisms and treatment recommendations","volume":"15","author":"Wang","year":"2024","journal-title":"Front Psychiatry"},{"key":"B78","doi-asserted-by":"publisher","first-page":"e21354","DOI":"10.7759\/cureus.21354","article-title":"Olanzapine-induced parkinsonism and akathisia: a case report","volume":"14","author":"Jaitpal","year":"2022","journal-title":"Cureus"},{"key":"B79","doi-asserted-by":"publisher","first-page":"108628","DOI":"10.1016\/j.isci.2023.108628","article-title":"Amylin receptor agonism enhances the effects of liraglutide in protecting against the acute metabolic side effects of olanzapine","volume":"27","author":"Medak","year":"2024","journal-title":"iScience"},{"key":"B80","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40360-025-00873-8","article-title":"Safety analysis of romiplostim, eltrombopag, and avatrombopag post-market approval: a pharmacovigilance study based on the FDA adverse event reporting system","volume":"26","author":"Wang","year":"2025","journal-title":"BMC Pharmacol Toxicol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1710507\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T07:03:24Z","timestamp":1770793404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1710507\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":80,"alternative-id":["10.3389\/fcvm.2026.1710507"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1710507","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"article-number":"1710507"}}